Warning: members of the public are being contacted by people claiming to work for AXA Investment Managers UK Limited.  Find out more information and what to do by clicking here.

Longevity Economy strategy: Strategy outperformed benchmark as COVID vaccine rollouts continued globally

  • 08 February 2021 (3 min read)

Key points

  • The strategy outperformed its benchmark in January, buoyed by digital health holdings
  • Optimism around COVID vaccine rollouts has been tempered by emergence of new, more transmissible variants
  • Focus remains on long-term changes brought about by ageing populations

What’s happening?

In January, Joe Biden was inaugurated as US President after a tumultuous transition period, the UK ended its transition period and began trading under a new agreement with the EU and COVID vaccine rollouts continued globally. Given the gravity of events and after a strong 2020 performance, it is no surprise that global markets took a pause in January with the MSCI AC World index falling a modest 0.5% in USD terms.

COVID-19 continues to dominate headlines. The emergence of new, more transmissible and possibly more deadly variants of COVID-19 makes it harder to predict when social distancing measures can be fully relaxed globally. However, it is reasonable to expect mortality rates to fall as vaccination programs start to offer protection to high risk groups. Preliminary evidence suggests the currently authorised vaccines provide protection against the most prevalent of the emerging variants of COVID-19, which offers reason for optimism.

Portfolio positioning and performance

The Longevity Economy strategy outperformed its reference benchmark in January. Strong contributions came from a number of our digital health holdings that are part of the fund’s Wellness theme, such as Tabula Rasa and Teladoc. Teladoc has become widely known during the COVID-19 pandemic as provider of virtual physician appointments, it has seen demand spike as people look to avoid visiting medical centres in favour of virtual interactions with healthcare professionals.

Tabula Rasa is perhaps less well-known but provides an invaluable service to patients with serious illnesses, and typically advanced age. Tabula Rasa’s suite of solutions improve management of chronically ill patients, for example by highlighting the risk of adverse drug-drug interactions that are a leading cause of hospitalisation in patients taking multiple drugs. The prevalence of chronic illness and consumption of prescription drugs correlates with increasing age, so solutions that can mitigate the risks of chronic disease medication management can improve outcomes for patients and healthcare systems.

Another positive contributor to performance was recreational boating company, Brunswick, which is part of the fund’s Silver Spending theme. The company has benefited recently from robust demand as consumers seek activities less impacted by social distancing measures.

In contrast, other leisure-exposed names, Las Vegas Sands and Royal Caribbean detracted from performance as resurgent virus cases lowered the prospect of a return to global travel and leisure demand.


The beginning of mass vaccination programs against COVID-19 increased optimism that social distancing measures may soon be relaxed in multiple regions. However, the emergence of more transmissible variants somewhat tempered these expectations. It is fair to say significant optimism is already reflected in share prices for many companies. Undoubtedly asset prices have been supported by unprecedented fiscal stimulus from governments in major economies. The stimulus has dwarfed the stimulus provided in the aftermath of the Global Financial Crisis. While this has supported many people and businesses who would have faced insolvency without financial support, it is likely that the debt raised to fund these measures will entail higher taxes over the long-term, which could subdue long-term economic potential.

The end of Brexit uncertainty provides greater clarity on the future trading relationship between the UK and EU and removes the long-perceived threat of no-deal. We are starting to see the key priorities of the Biden administration in the US, with the economic fallout of COVID-19 and the climate crisis high on the agenda. Time will tell if additional stimulus can be agreed by Congress given the Democrats narrow working majorities in both chambers.

Stepping back from macroeconomic considerations, we retain the view that high quality management teams, operating businesses with a sustainable competitive advantage and with the benefit of secular tailwinds are well-placed to navigate the current disruption. Despite the headwinds many businesses have faced over the last 12 months, the unshakeable conclusion on the outlook for the Longevity Economy is that the global population continues to age and this creates opportunities for companies that are positioned to benefit from long-term changes in consumption patterns that ageing populations will bring.

No assurance can be given that the Longevity Economy Strategy will be successful. Investors can lose some or all of their capital invested. The Longevity Economy Strategy is subject to risks including: Equity; Currency; Global Investments; Emerging markets; Investments in small capitalisation universe and Investment in specific asset classes.

Have our latest insights delivered straight to your inbox

Subscribe to updates.

    Not for Retail distribution

    This document is intended exclusively for Professional, Institutional, Qualified or Wholesale Clients / Investors only, as defined by applicable local laws and regulation. Circulation must be restricted accordingly.

    This promotional communication does not constitute investment research or financial analysis relating to transactions in financial instruments as per MIF Directive (2014/65/EU), nor does it constitute on the part of AXA Investment Managers or its affiliated companies an offer to buy or sell any investments, products or services, and should not be considered as solicitation or investment, legal or tax advice, a recommendation for an investment strategy or a personalized recommendation to buy or sell securities.

    Due to its simplification, this document is partial and opinions, estimates and forecasts herein are subjective and subject to change without notice. There is no guarantee that forecasts made will come to pass. Data, figures, declarations, analysis, predictions and other information in this document is provided based on our state of knowledge at the time of creation of this document. Whilst every care is taken, no representation or warranty (including liability towards third parties), express or implied, is made as to the accuracy, reliability or completeness of the information contained herein. Reliance upon information in this material is at the sole discretion of the recipient. This material does not contain sufficient information to support an investment decision.

    Before making an investment, investors should read the relevant Prospectus and the Key Investor Information Document / scheme documents, which provide full product details including investment charges and risks. The information contained herein is not a substitute for those documents or for professional external advice.

    The products or strategies discussed in this document may not be registered nor available in your jurisdiction. Please check the countries of registration with the asset manager, or on the web site https://www.axa-im.com/en/registration-map, where a fund registration map is available. In particular units of the funds may not be offered, sold or delivered to U.S. Persons within the meaning of Regulation S of the U.S. Securities Act of 1933. The tax treatment relating to the holding, acquisition or disposal of shares or units in the fund depends on each investor’s tax status or treatment and may be subject to change. Any potential investor is strongly encouraged to seek advice from its own tax advisors.

    Past performance is not a guide to current or future performance, and any performance or return data displayed does not take into account commissions and costs incurred when issuing or redeeming units. The value of investments, and the income from them, can fall as well as rise and investors may not get back the amount originally invested. Exchange-rate fluctuations may also affect the value of their investment. Due to this and the initial charge that is usually made, an investment is not usually suitable as a short term holding.

    Risk Warning

    The value of investments, and the income from them, can fall as well as rise and investors may not get back the amount originally invested. 

    Are you an IFA or other Professional Investor ?

    Are you a financial advisor, institutional, or other professional investor?

    This section is for professional investors only. You need to confirm that you have the required investment knowledge and experience to view this content. This includes understanding the risks associated with investment products, and any other required qualifications according to the rules of your jurisdiction.